Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Molecular Partners
Thumbnail
April 27, 2022

A bad day for Molecular Partners

Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.

Thumbnail
January 10, 2022

JP Morgan 2022 – day one sees healthy deal flow from biopharma

But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.

Article image
Vantage logo
November 17, 2021

Atea’s woes grow while other Covid readouts approach

Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.

Article image
Vantage logo
November 16, 2021

Molecular Partners' Covid-19 therapy proves inactiv

Article image
Vantage logo
July 28, 2021

Amgen doubles down on bispecifics, courtesy of Teneobio

Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.

Article image
Vantage logo
June 30, 2021

Early data confirm Atea’s Covid antiviral as one to watch

Article image
Vantage logo
May 27, 2021

US appetite for Covid-19 treatments remains undiminished

With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.

Article image
Vantage logo
April 15, 2021

Merck’s Covid-19 push narrows further

Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.

Article image
Vantage logo
March 08, 2021

Molnupiravir’s big day draws near

Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.

Article image
Vantage logo
June 26, 2020

US regulator still doesn’t buy abicipar

Article image
Vantage logo
June 04, 2020

Here come the anti-Covid antibodies

Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.